Revance Therapeutics (RVNC) Received its Third Buy in a Row

By Jason Carr

After Needham and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price target of $34.00. The company’s shares closed last Monday at $19.10.

According to TipRanks.com, Yang is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.7% and a 37.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Audentes Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $31.29, which is a 67.3% upside from current levels. In a report issued on November 25, Needham also maintained a Buy rating on the stock with a $32.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.99 and a one-year low of $9.88. Currently, Revance Therapeutics has an average volume of 380K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.